MAGEA3 and non-small cell lung carcinoma: However, preliminary findings from the early phase II clinical trial suggested that patients with MAGE-A3 positive resected NSCLC at stages IB, II, or IIIA experienced a 43% reduction in the relative risk of relapse compared to those receiving a placebo [24].